Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction

被引:55
作者
Mocan, Mihaela [1 ,2 ]
Hognogi, Larisa Diana Mocan [1 ,3 ]
Anton, Florin Petru [1 ,3 ]
Chiorescu, Roxana Mihaela [1 ,3 ]
Goidescu, Cerasela Mihaela [1 ,3 ]
Stoia, Mirela Anca [1 ,3 ]
Farcas, Anca Daniela [1 ,3 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med, Cluj Napoca, Romania
[2] Emergency Clin Cty Hosp, Dept Internal Med, Cluj Napoca, Romania
[3] Emergency Clin Cty Hosp, Dept Cardiol, Cluj Napoca, Romania
关键词
D O I
10.1155/2019/7583690
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Left ventricular diastolic dysfunction (LVDD) is an important precursor to many different cardiovascular diseases. Diastolic abnormalities have been studied extensively in the past decade, and it has been confirmed that one of the mechanisms leading to heart failure is a chronic, low-grade inflammatory reaction. The triggers are classical cardiovascular risk factors, grouped under the name of metabolic syndrome (MetS), or other systemic diseases that have an inflammatory substrate such as chronic obstructive pulmonary disease. The triggers could induce myocardial apoptosis and reduce ventricular wall compliance through the release of cytokines by multiple pathways such as (1) immune reaction, (2) prolonged cell hypoxemia, or (3) excessive activation of neuroendocrine and autonomic nerve function disorder. The systemic proinflammatory state causes coronary microvascular endothelial inflammation which reduces nitric oxide bioavailability, cyclic guanosine monophosphate content, and protein kinase G (PKG) activity in adjacent cardiomyocytes favoring hypertrophy development and increases resting tension. So far, it has been found that inflammatory cytokines associated with the heart failure mechanism include TNF-, IL-6, IL-8, IL-10, IL-1, IL-1, IL-2, TGF-, and IFN-. Some of them could be used as diagnosis biomarkers. The present review aims at discussing the inflammatory mechanisms behind diastolic dysfunction and their triggering conditions, cytokines, and possible future inflammatory biomarkers useful for diagnosis.
引用
收藏
页数:14
相关论文
共 109 条
[1]   Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial [J].
Anand, Inder S. ;
Rector, Thomas S. ;
Kuskowski, Michael ;
Snider, James ;
Cohn, Jay N. .
CIRCULATION-HEART FAILURE, 2014, 7 (03) :418-U70
[2]   Insulin Resistance and Heart Failure: Molecular Mechanisms [J].
Aroor, Annayya R. ;
Mandavia, Chirag H. ;
Sowers, James R. .
HEART FAILURE CLINICS, 2012, 8 (04) :609-+
[3]   Preclinical Left Ventricular Diastolic Dysfunction in Metabolic Syndrome [J].
Ayalon, Nir ;
Gopal, Deepa M. ;
Mooney, Deirdre M. ;
Simonetti, Juliana S. ;
Grossman, Jason R. ;
Dwivedi, Aeshita ;
Donohue, Courtney ;
Perez, Alejandro J. ;
Downing, Jill ;
Gokce, Noyan ;
Miller, Edward J. ;
Liang, Chang-seng ;
Apovian, Caroline M. ;
Colucci, Wilson S. ;
Ho, Jennifer E. .
AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (06) :838-842
[4]   Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load [J].
Bartunek, Jozef ;
Delrue, Leen ;
Van Durme, Frederik ;
Muller, Olivier ;
Casselman, Filip ;
De Wiest, Bart ;
Croes, Romaric ;
Verstreken, Sofie ;
Goethals, Marc ;
de Raedt, Herbert ;
Weinberg, Ellen O. ;
Vanderheyden, Marc ;
Sarma, Jaydeep ;
Joseph, Lija .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (25) :2166-2174
[5]   Soluble ST2 for Prognosis and Monitoring in Heart Failure The New Gold Standard? [J].
Bayes-Genis, Antoni ;
Nunez, Julio ;
Lupon, Josep .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (19) :2389-2392
[6]   ST2 Pathogenetic Profile in Ambulatory Heart Failure Patients [J].
Bayes-Genis, Antoni ;
Januzzi, James L. ;
Gaggin, Hanna K. ;
de Antonio, Marta ;
Motiwala, Shweta R. ;
Zamora, Elisabet ;
Galan, Amparo ;
Domingo, Mar ;
Urrutia, Agustin ;
Lupon, Josep .
JOURNAL OF CARDIAC FAILURE, 2015, 21 (04) :355-361
[7]  
Bozkurt B, 2017, J AM COLL CARDIOL, V70, P776, DOI [10.1161/CIR, DOI 10.1016/J.JACC.2017.04.025]
[8]   Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction [J].
Chan, Michelle M. Y. ;
Santhanakrishnan, Rajalakshmi ;
Chong, Jenny P. C. ;
Chen, Zhaojin ;
Tai, Bee Choo ;
Liew, Oi Wah ;
Ng, Tze Pin ;
Ling, Lieng H. ;
Sim, David ;
Leong, Toh G. ;
Yeo, Poh Shuan Daniel ;
Ong, Hean-Yee ;
Jaufeerally, Fazlur ;
Wong, Raymond Ching-Chiew ;
Chai, Ping ;
Low, Adrian F. ;
Richards, Arthur M. ;
Lam, Carolyn S. P. .
EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (01) :81-88
[9]   Effect of Rosuvastatin on Cardiac Remodeling, Function, and Progression to Heart Failure in Hypertensive Heart With Established Left Ventricular Hypertrophy [J].
Chang, Sung-A ;
Kim, Yong-Jin ;
Lee, Hye-Won ;
Kim, Dae-Hee ;
Kim, Hyung-Kwan ;
Chang, Hyuk-Jae ;
Sohn, Dae-Won ;
Oh, Byung-Hee ;
Park, Young-Bae .
HYPERTENSION, 2009, 54 (03) :591-U278
[10]   Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials [J].
Chen, Yanmei ;
Wang, He ;
Lu, Yongkang ;
Huang, Xiaobo ;
Liao, Yulin ;
Bin, Jianping .
BMC MEDICINE, 2015, 13